Bank Of America Corp Rubius Therapeutics, Inc. Transaction History

Bank Of America Corp

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Feb 10, 2023	BUY	$0.14 - $0.31 $2,251 - $4,984	16,079 Added 501.37%	19,286 $3,000
Q3 2022 Nov 14, 2022	SELL	$0.46 - $1.29 $95,838 - $268,763	-208,344 Reduced 98.48%	3,207 $1,000
Q2 2022 Aug 12, 2022	BUY	$0.79 - $5.98 $63,005 - $476,928	79,754 Added 60.51%	211,551 $179,000
Q1 2022 May 16, 2022	BUY	$4.25 - $10.4 $293,560 - $718,359	69,073 Added 110.12%	131,797 $726,000
Q4 2021 Feb 08, 2022	BUY	$9.68 - $17.74 $205,874 - $377,294	21,268 Added 51.3%	62,724 $607,000
Q3 2021 Nov 15, 2021	BUY	$17.6 - $25.91 $452,056 - $665,498	25,685 Added 162.86%	41,456 $741,000
Q2 2021 Sep 13, 2021	BUY	$22.26 - $28.43 $351,062 - $448,369	15,771 New	15,771 $384,000

325

Ticker RUBY
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 90,357,000
Description
Rubius Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of red cell therapeutics (RCTs) for the treatment of patients with severe diseases. The company is developing RTX-240 and RTX-224 for the treatment of solid tumors cancer; and RTX-aAPC to treat cancers. It is also developing RTX-321 for the treatmen...

Get notified when there are updates to the investment portfolio of Bank Of America Corp , based on Form 13F filings with the SEC.

Stay updated on Bank Of America Corp with notifications on news.